Used in the treatment of hemophilia A and B to reduce bleeding episodes by inhibiting tissue factor pathway inhibitor (TFPI), thereby enhancing thrombin generation and promoting blood clot formation. It functions as a long-acting subcutaneous therapy, offering an alternative to traditional factor replacement or frequent infusions. Particularly beneficial for patients with inhibitors to factor VIII or IX, it supports prophylactic management and improves quality of life through less frequent dosing and effective hemostatic control.